Status: Recruiting
SGLT2i Therapy in Islet Transplantation (SIT)
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Participants needed: 40
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: University of MinnesotaUpdated: Jul 22, 2026Locations: 1
Eligibility criteria
Age 18-70 years old; [+8]
HbA1c >9%; on any non-insulin antihyperglycemic medication; [+11]